This trial is active, not recruiting.

Condition multiple myeloma
Treatment acy-1215 in combination with pomalidomide and dexamethasone
Phase phase 1
Target HDAC
Sponsor Acetylon Pharmaceuticals Incorporated
Start date August 2014
End date August 2016
Trial size 20 participants
Trial identifier NCT02189343, ACE-MM-104


To determine the maximum tolerated dose (MTD), if present, and dose schedule of ACY-1215 (ricolinostat) in combination with pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety study
Intervention model single group assignment
Masking open label
Dose Escalating Cohorts of ACY-1215 in combination with pomalidomide and dexamethasone.
acy-1215 in combination with pomalidomide and dexamethasone ACY-1215 (Ricolinostat)
Escalating dose Cohorts to determine a potential Maximum Tolerated Dose to recommend for a dosing schedule.

Primary Outcomes

Determine Maximum Tolerated Dose (MTD) if any, and recommended dose schedule
time frame: Every 56 days on treatment, estimated average of 4 months.

Secondary Outcomes

time frame: Upon completion of a 28-day treatment cycle and for the duration of treatment, an estimated average of 4 months.
Anti-Tumor Activity
time frame: Upon completion of a 28-day treatment cycle and for the duration of treatment, an estimated average of 4 months.
time frame: Up to 8 days post first dose
time frame: Up to 24 hours post first dose

Eligibility Criteria

Male or female participants at least 18 years old.

Key Inclusion Criteria Includes: Patients meeting all of the following criteria may be enrolled in the study: 1. Must be able to understand and voluntarily sign an ICF. 2. Must be registered into the mandatory POMALYST Risk Evaluation and Mitigation Strategy (REMS)™ program, and be willing and able to comply with the requirements of the POMALYST REMS™ program (Appendix 9.3). 3. Must be ≥ 18 years of age at the time of signing the ICF. 4. Must be able to adhere to the study visit schedule and other protocol requirements. 5. Must have a documented diagnosis of MM and have relapsed or relapsed and refractory disease. Patients must have received at least 2 lines of prior therapies. Patients must have relapsed after having achieved at least stable disease for at least 1 cycle of treatment to at least 1 prior regimen and then developed PD. Relapsed and relapsed-and-refractory patients must have documented evidence of PD during or within 60 days (measured from the end of the last cycle) of completing treatment with the last antimyeloma drug regimen used just prior to study entry. 6. Patients must have undergone prior treatment with at least 2 cycles of lenalidomide and at least 2 cycles of a proteasome inhibitor (either in a separate regimen or within the same regimen. 7. Must not be a candidate for autologous stem cell transplant (ASCT), have declined the option of ASCT, or have relapsed after prior ASCT. 8. Must have measurable levels of myeloma paraprotein in serum (≥ 0.5 g/dL) or urine (≥ 0.2 g/24 hours). Patients who do not have myeloma paraprotein must have serum free light chain (SFLC) concentration of ≥ 10 mg/dL, provided SFLC ratio is abnormal. Nonsecretory myeloma is excluded. 9. Must have Eastern Cooperative Oncology Group performance status score of 0, 1, or 2. 10. Females of childbearing potential must have a negative serum or urine pregnancy test as described in Appendix 9.3 for the POMALYST REMS™ program. Females of childbearing potential and males must either commit to continued abstinence from heterosexual intercourse or must abide by birth control requirements as described in Appendix 9.3 for the POMALYST REMS™ program. 11. Must agree to refrain from donating blood while on study drug and for 28 days after discontinuation from this study. 12. Must agree not to share study medication with another person. 13. Must be able to take ASA (81 or 325 mg) daily as prophylactic anticoagulation. Patients intolerant to ASA may use low molecular weight heparin. Lovenox is recommended. Coumadin will be allowed provided the patient is fully anticoagulated, with an international normalized ratio of 2 to 3. Key Exclusion Criteria Includes: Patients meeting any of the following criteria will be excluded from enrollment in the study: 1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from signing the ICF or from following the study requirements. 2. Pregnant or lactating females. 3. Prior therapy with histone deacetylase inhibitor or pomalidomide. 4. Any of the following laboratory abnormalities: - ANC < 1,000/µL - Platelet count < 75,000/ µL for patients in whom < 50% of bone marrow nucleated cells are plasma cells, or a platelet count < 50,000 for patients in whom ≥ 50% of bone marrow nucleated cells are plasma cells - Hemoglobin < 8 g/dL (< 4.9 mmol/L; prior red blood cell transfusion or recombinant human erythropoietin use is permitted). - Creatinine clearance < 45 mL/min according to Cockcroft-Gault formula. If creatinine clearance calculated from the 24 hour urine sample is ≥ 45 mL/min, patient will qualify for the trial. - Serum glutamic oxaloacetic transaminase/aspartate aminotransferase, or serum glutamic pyruvic transaminase/alanine aminotransferase > 3.0 × ULN - Serum total bilirubin > 2.0 mg/dL 5. Prior history of malignancies, other than MM, unless the patient has been free of the disease for ≥ 3 years. Exceptions include the following: - Basal or squamous cell carcinoma of the skin - Ductal carcinoma in situ; or cervical intraepithelial neoplasia - Carcinoma of the prostate with a current prostate-specific antigen below the upper limit of normal 6. Corrected QT interval (QTc) using Fridericia's formula value > 480 msec at Screening; family or personal history of long QTc syndrome or ventricular arrhythmias including ventricular bigeminy at Screening; previous history of drug-induced QTc prolongation or the need for treatment with medications known or suspected of producing prolonged QTc intervals on electrocardiogram. 7. Known human immunodeficiency virus, hepatitis B virus, and known or suspected active hepatitis C virus infection. 8. Hypersensitivity to thalidomide, lenalidomide, pomalidomide, or dexamethasone (such as Steven Johnson Syndrome). Hypersensitivity, such as rash, that can be medically managed is allowable. 9. Peripheral neuropathy ≥ Grade 2 despite supportive therapy. 10. Radiotherapy or systemic therapy (standard or an investigational or biologic anticancer agent) within 14 days of initiation of study drug treatment. 11. Current enrollment in another clinical trial involving treatment and/or receiving an investigational agent for any reason. 12. Inability or unwillingness to comply with birth control requirements or any of the POMALYST REMS™ requirements per Appendix 9.3.

Additional Information

Official title A Phase 1B Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety and Anti-Tumor Activity of an Alternative Liquid Formulation of ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
Principal investigator Sumit Madan, MD
Description To determine the maximum tolerated dose (MTD), if present, and to identify a recommended dose and schedule of ricolinostat administered in an alternative liquid formulation (ALF) (10mg/mL) in combination with pomalidomide and low-dose dexamethasone in patients with relapsed or relapsed-and-refractory multiple myeloma. To evaluate the safety and any anti-tumor activity of ricolinostat administered in combination with pomalidomide and dexamethasone as treatment for patients with relapsed or relapsed-and-refractory multiple myeloma, including duration of response. To assess the Pharmacokinetics and Pharmacodynamics of all three medications administered in combination, and to assess the Pharmacokinetics of ricolinostat and pomalidomide specifically. An evaluation of the relationship between response and biomarkers relating to interacellular acetylation may also be completed.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Acetylon Pharmaceuticals Incorporated.